Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

27.97 -0.10 (-0.36%)
Official Closing Price Updated: 7:00 PM EDT, Aug 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
D-Wave Quantum vs. Rigetti Computing: Which Quantum Computing Stock Is a Better Investment in 2026? ↗
While both D-Wave and Rigetti's revenues have been volatile, their valuations tell a starkly different story for quantum investors. 
Via The Motley Fool
News headline image
Prediction: This Is Where Pfizer Stock Will Be in 2030 ↗
Pfizer is facing material patent expirations over the next two years, but that will be over by 2030. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Dividend ETF That Generates Passive Income While You Sleep ↗
Income generation is more about finding consistency than finding an ultra-high yield. 
Via The Motley Fool
Topics ETFs
News headline image
3 of Wall Street’s Favorite Stocks We’re Skeptical Of
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
News headline image
2 Reasons to Watch PFE and 1 to Stay Cautious
Pfizer has been treading water for the past six months, recording a small return of 2.6% while holding steady at $27.76. The stock also fell short of the S&P... 
Via StockStory
Topics Supply Chain
News headline image
1 S&P 500 Stock to Research Further and 2 That Underwhelm
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch... 
Via StockStory
Topics Stocks
News headline image
Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight ↗
Healthcare stocks saw mixed after-hours moves, with Moderna and Merck cooling after explosive gains on positive cancer trial results. 
Via Benzinga
News headline image
Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript ↗
CEO Rajavelu discusses $105 million financing and SP001 immunology strategy. 
Via The Motley Fool
Topics Earnings
News headline image
Stock Market Today, Aug. 19: Moderna Skyrockets 177% on Positive Phase 3 Melanoma Data ↗
Today, Aug. 19, 2026, Moderna's personalized cancer vaccine met its late-stage goal, with the company and Merck planning an FDA submission. 
Via The Motley Fool
Topics Stocks
News headline image
Why Pfizer (PFE) Stock Is Trading Up Today
What Happened? Shares of global pharmaceutical company Pfizer (NYSE:PFE) jumped 3.8% in the afternoon session after positive clinical trial results from peer... 
Via StockStory
Topics World Trade
News headline image
Merck Just Raised the Stakes for Pfizer's Cancer Vaccine Ambitions ↗
Merck's deeper push into personalized cancer vaccines raises the competitive bar for Pfizer, BioNTech in biotech's fastest-growing race. 
Via Benzinga
What's going on in today's session: S&P500 most active stocks ↗
Via Chartmill
News headline image
Pfizer Stock Rises Wednesday: What's Going On? ↗
Pfizer Inc (NYSE:PFE) shares are trading higher Wednesday, moving in sympathy with mRNA cancer vaccine-related companies after Merck & Co Inc (NYSE:MRK) and Moderna Inc (NASDAQ:MRNA) announced that... 
Via Benzinga
News headline image
Protalix (PLX) Q2 2026 Earnings Call Transcript ↗
Elfabrio sales surge drives $19.9M quarterly revenue and $22.1M H1 net income. 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
3 S&P 500 Stocks We Keep Off Our Radar
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch... 
Via StockStory
Topics Fraud Stocks
Curious about the most active S&P500 stocks in today's session? ↗
Via Chartmill
News headline image
Warren Buffett and Greg Abel Keep Overlooking This Stock -- but It's One of the Most Berkshire-Ready Picks on the Market ↗
Even if Berkshire Hathaway never scoops up a stake on this largely overlooked and mostly unloved name, that doesn't mean it doesn't have a place in your portfolio. 
Via The Motley Fool
News headline image
2 Profitable Stocks with Solid Fundamentals and 1 We Ignore
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
News headline image
3 Stocks Under $50 We’re Skeptical Of
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However... 
Via StockStory
These S&P500 stocks are the most active in today's session ↗
Via Chartmill
News headline image
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗
Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think. 
Via The Motley Fool
News headline image
European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application ↗
Valneva (VALN) stock surges after EMA validates MAA for Lyme disease vaccine candidate developed with Pfizer (PFE). Phase 3 trial showed efficacy and no safety concerns, pending regulatory approval. 
Via Benzinga
News headline image
Recent Filing Shows That Rep. Carol Miller Sold Over $60K Worth of Pfizer Stock ↗
A August filing shows that Representative Carol Miller reported a sale in Pfizer (NYSE:PFE), valued between $60,004 and $200,000. The transaction date is listed as March 10, 2025, with the report... 
Via Benzinga
News headline image
Vanguard Is "Cautious" on U.S. Growth Stocks. These 2 Value ETFs Could Be Smarter Buys for Long-Term Investors. ↗
In the next 10 years, underrated sectors and undervalued companies might beat the biggest names of the AI trade. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
From Pfizer Inc.
Via Business Wire
News headline image
Valneva Q2 Earnings Call Highlights ↗
Valneva (NASDAQ:VALN) reported lower first-half revenue and wider losses for 2026, while maintaining its full-year sales outlook and emphasizing its cash position, restructuring measures and... 
Via MarketBeat
Topics Earnings
What's going on in today's session: S&P500 most active stocks ↗
Via Chartmill
News headline image
2 Large-Cap Stocks for Long-Term Investors and 1 We Avoid
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are... 
Via StockStory
Which S&P500 stocks are the most active on Wednesday? ↗
Via Chartmill
News headline image
Rigel (RIGL) Q2 2026 Earnings Call Transcript ↗
VEPPANU launch and R289 data readouts drive second-half priorities. 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.